GT Medical Technologies revealed that financial and operational life sciences leader James Leech has joined the company as chief financial and strategy officer.
Leech will collaborate with the team to accelerate commercial opportunities for GammaTile radiation treatment for the brain. He will also spearhead corporate strategy and development, as well as financial and investor management.
Previously, Leech was chief financial officer of orthopedic device company Moximed. Before that, he was chief business officer at Palette Life Sciences from the company’s inception through its acquisition by Teleflex in 2023. He began his career in life science investment banking and strategy consulting.
Notably, Leech brings cross-border experience, having executed transactions and operational initiatives on behalf of and involving companies in the EU and APAC.
“We are excited to welcome James as he assumes the Chief Financial and Strategy Officer role at GT Medical Technologies,” said Per Langoe, CEO of GT Medical Technologies. “I look forward to collaborating with him to ensure even more doctors and patients have access to GammaTile. With over 10 years of successful experience leading commercial-stage healthcare-focused companies in an advisory and operational capacity, his expertise on a range of traditional and complex financial and strategic management areas provides us with a substantial opportunity for continued growth and adoption.”
GammaTile radiation therapy is placed at the time of tumor removal surgery from the brain. It delivers immediate, targeted radiation to the tumor site. It removes the treatment gap between surgery and radiation therapy to allow for wound healing. Delivering radiation therapy this way, according to the company, can maximize treatment effectiveness against remaining cancer cells and reduce risk of regrowth.
Earlier this year, GT Medical Technologies collected $37 million in a first close Series D financing round led by Evidity Health Capital. The company said the money will accelerate completion of the ROADS clinical study, which is focused on GammaTile for newly diagnosed brain metastases, and the GESTALT clinical trial for patients with newly diagnosed glioblastoma
“I look forward to joining a leadership team that is dedicated to transforming the lives of patients with brain tumors,” said Leech. “GT Medical Technologies is poised for significant growth, and I am thrilled to collaborate with all stakeholders to optimize the company’s continued expansion of GammaTile, our FDA-cleared bioresorbable radiotherapy implant for the treatment of brain tumors.”
link